Peri-implantitis Active
Conditions
Interventions
L8020 is administered topically in the peri-implant groove for peri-implantitis with drainage. (However, if there are multiple cases of peri-implantitis with suppuration, the implant with the longest
Sponsors
Yasuda Keisuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Persons who are 18 years of age or older at the time consent is obtain 2. Those who can obtain written consent from the individual to participate in this study 3. Patients with implants that meet the diagnostic criteria for peri-implantitis for at least one year at the time of study entry. Peri-implantitis is defined as patients who meet the following diagnostic criteria i) Inflammation around the implant ii) Bone resorption around the implant 4. Patients with implants that have been known to drain for at least 3 months and have drained within 1 week prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. Patients who have received a lactic acid bacteria preparation, bifidobacteria preparation, butyric acid bacteria preparation, or this drug as a prescription drug within 3 months prior to the start of administration of this drug. 2. Patients who have experienced serious adverse reactions to lactic acid bacteria, bifidobacteria, butyric acid bacteria, or this drug as ethical drugs in the past. 3. Patients who have received antimicrobial agents administered topically in the oral cavity or systemically by oral administration, etc. within 7 days. 4. Patients already using this drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement rate to peri-implantitis Remission after 7 days of L8020 treatment in patients with peri-implantitis Active | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the structure of the bacterial flora comprising the peri-implant sulcus | — |
Contacts
Public ContactYuhei Hashimoto
Hiroshima University Hospital
Outcome results
None listed